Singapore Startup Raises $3M for Synthetic Skin Treatment

Healing a serious wound might soon get easier, cheaper, and more accessible thanks to a lab-grown skin substitute that doesn't need animals or cold storage.

Bioactivx, a Singapore deep-tech startup, raised $3 million in fresh funding to scale up production of Bioactiv Matrix, a fully synthetic material that speeds tissue regeneration and reduces inflammation. The company has now secured nearly $5 million total since its launch from Singapore's Agency for Science, Technology and Research and the SingHealth healthcare group.

Traditional wound treatments often rely on collagen from animals or require skin grafts, both of which need refrigeration and sterile operating rooms. That makes them impractical for emergency responders, military medics, or clinics in rural areas with limited resources.

Bioactivx's product sidesteps all those limitations. The synthetic material works at room temperature and can be applied outside hospitals, opening doors for battlefield medicine, disaster response, and underserved communities.

The funding round drew support from venture firm Cocoon Capital and Swiss family office ContInvest. Bioactivx plans to use the money to expand manufacturing in Singapore, build out its regulatory and commercial teams, and run post-market clinical trials.

The company is also developing treatments for chronic wounds, diabetic ulcers, and inflammatory skin conditions. These applications could help millions of people worldwide who struggle with wounds that won't heal.

The Ripple Effect

Bioactivx already submitted its full data package to Singapore's Health Sciences Authority and aims to launch locally by late 2026. From there, the company plans regional expansion in 2027, with U.S. Food and Drug Administration and European Union filings on the horizon.

The timeline includes a clinical feasibility study and Series A fundraising in 2026, followed by automated manufacturing in 2027. By 2028, Bioactivx hopes to establish its first overseas production facility and regional headquarters.

The shift from animal-derived to synthetic materials represents more than convenience. It means consistent quality, no risk of disease transmission, and independence from supply chain disruptions that affect biological products.

For medics treating traumatic injuries in the field or nurses caring for diabetic patients in remote villages, this technology could mean the difference between slow healing and swift recovery.

Singapore continues building its reputation as a biotech innovation hub, with startups like Bioactivx spinning out from government research agencies to tackle real-world medical challenges. A wound care revolution is about to reach the people who need it most.